Kinomica
Kinomica is applying phosphoproteomics to cancer diagnostics and precision medicine with the goal of helping clinicians select the right therapy for the right patient at the right time. They have developed KScan®, a phosphoproteomic diagnostic platform, to realize the full potential of precision medicine. The company focuses on questions such as identifying the best drugs for individual patients, finding alternative drugs for non-responders or relapsed patients, and developing better drugs through phosphoproteomics. Their technologies include liquid chromatography mass spectrometry, spectral peak identification and quantification, ML-derived predictive assays, and algorithms for measuring kinase activity. They are developing multi-drug diagnostics for diseases like hepatocellular carcinoma and acute myeloid leukemia.
Industries
Nr. of Employees
small (1-50)
Kinomica
Alderley Park, Cheshire, United Kingdom, Europe
Products
Phosphoproteomic diagnostic platform
A mass spectrometry–based diagnostic platform that measures phosphorylation and signaling activity to support selection of therapies for individual patients.
Phosphoproteomic diagnostic platform
A mass spectrometry–based diagnostic platform that measures phosphorylation and signaling activity to support selection of therapies for individual patients.
Services
Phosphoproteomic profiling service (cell signalling profiling)
Laboratory-based profiling service that measures phosphorylation and ranks enzyme/kinase activity in tissue samples to support biomarker discovery and drug-response prediction.
Mass spectrometry data analysis and bioinformatics
Data processing and interpretation service for SWATH-MS, DDA and other LC-MS/MS datasets, including spectral identification, quantification and protein identification workflows.
Development of predictive phosphoproteomic assays
Development of machine learning–derived assays from phosphoproteomic data to predict patient response to specific therapies or combinations.
Phosphoproteomic profiling service (cell signalling profiling)
Laboratory-based profiling service that measures phosphorylation and ranks enzyme/kinase activity in tissue samples to support biomarker discovery and drug-response prediction.
Mass spectrometry data analysis and bioinformatics
Data processing and interpretation service for SWATH-MS, DDA and other LC-MS/MS datasets, including spectral identification, quantification and protein identification workflows.
Development of predictive phosphoproteomic assays
Development of machine learning–derived assays from phosphoproteomic data to predict patient response to specific therapies or combinations.
Expertise Areas
- Phosphoproteomic biomarker discovery
- Clinical diagnostic development for oncology
- Mass spectrometry proteomics (LC-MS/MS, SWATH, DDA)
- Proteomics bioinformatics and software
Key Technologies
- Phosphoproteomics
- Liquid chromatography–tandem mass spectrometry (LC-MS/MS)
- SWATH-MS
- Data-dependent acquisition (DDA)